<DOC>
	<DOCNO>NCT01122511</DOCNO>
	<brief_summary>This study evaluate safety efficacy dexamethasone ( OZURDEX® ) adjunctive therapy ranibizumab ( LUCENTIS® ) compare ranibizumab alone treatment patient choroidal neovascularization secondary age-related macular degeneration</brief_summary>
	<brief_title>Safety Efficacy Dexamethasone Adjunctive Therapy Ranibizumab Subjects With Choroidal Neovascularization Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Received least 2 3 monthly Lucentis Avastin injection Last Lucentis Avastin inject approximately 4 week prior screen Visual acuity 20/320 20/40 Active ocular infection Contraindication pupil dilation either eye Eye surgery include cataract surgery and/or laser type within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>